Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

α4-integrin deficiency in B cells does not affect disease in a T-cell-mediated EAE disease model.

Hussain RZ, Cravens PD, Miller-Little WA, Doelger R, Granados V, Herndon E, Okuda DT, Eagar TN, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 16;6(4):e563. doi: 10.1212/NXI.0000000000000563. eCollection 2019 Jul.

2.

Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.

Cummings M, Arumanayagam ACS, Zhao P, Kannanganat S, Stuve O, Karandikar NJ, Eagar TN.

PLoS One. 2018 Aug 8;13(8):e0200752. doi: 10.1371/journal.pone.0200752. eCollection 2018.

3.

Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.

Islam AK, Sinha N, DeVos JM, Kaleekal TS, Jyothula SS, Teeter LD, Nguyen DTM, Eagar TN, Moore LW, Puppala M, Wong STC, Knight RJ, Frost AE, Graviss EA, Osama Gaber A.

Clin Transplant. 2017 Aug;31(8). doi: 10.1111/ctr.13028. Epub 2017 Jul 7.

PMID:
28658512
4.

The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes.

Loucks-DeVos JM, Eagar TN, Gaber AO, Patel SJ, Teeter LD, Graviss EA, Knight RJ.

Clin Transplant. 2017 Aug;31(8). doi: 10.1111/ctr.13025. Epub 2017 Jul 4.

PMID:
28582797
5.

Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307.

Long SW, Olsen RJ, Eagar TN, Beres SB, Zhao P, Davis JJ, Brettin T, Xia F, Musser JM.

MBio. 2017 May 16;8(3). pii: e00489-17. doi: 10.1128/mBio.00489-17.

6.

A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR.

Arellano B, Hussain R, Miller-Little WA, Herndon E, Lambracht-Washington D, Eagar TN, Lewis R, Healey D, Vernino S, Greenberg BM, Stüve O.

PLoS One. 2016 Apr 7;11(4):e0152720. doi: 10.1371/journal.pone.0152720. eCollection 2016.

7.

T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Raphael I, Nalawade S, Eagar TN, Forsthuber TG.

Cytokine. 2015 Jul;74(1):5-17. doi: 10.1016/j.cyto.2014.09.011. Epub 2014 Oct 30. Review.

8.

Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Deason K, Castro-Rojas C, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):9-17. doi: 10.1016/j.jneuroim.2014.08.622. Epub 2014 Aug 30. Review.

9.

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.

Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):232-5. doi: 10.1016/j.jneuroim.2014.08.624. Epub 2014 Sep 2.

10.

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN.

J Neuroimmunol. 2013 Jan 15;254(1-2):63-8. doi: 10.1016/j.jneuroim.2012.09.008. Epub 2012 Oct 1.

11.

Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.

Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O.

J Neuroinflammation. 2011 Jun 24;8:73. doi: 10.1186/1742-2094-8-73.

12.

DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Stüve O, Eagar TN, Rosenberg RN.

Cell Mol Neurobiol. 2011 Aug;31(6):867-74. doi: 10.1007/s10571-011-9680-7. Epub 2011 Apr 6.

13.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN.

PLoS One. 2011 Feb 16;6(2):e17103. doi: 10.1371/journal.pone.0017103.

14.

Reversible alopecia associated with glatiramer acetate.

Pacheco MF, Jacobe H, Eagar TN, Stüve O.

Arch Neurol. 2010 Sep;67(9):1154. doi: 10.1001/archneurol.2010.195. No abstract available.

PMID:
20837867
15.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL.

Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516.

16.

Translational research in neurology and neuroscience 2010: multiple sclerosis.

Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN.

Arch Neurol. 2010 Nov;67(11):1307-15. doi: 10.1001/archneurol.2010.158. Epub 2010 Jul 12. Review.

17.

Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.

Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN.

Vaccine. 2010 Jul 19;28(32):5280-7. doi: 10.1016/j.vaccine.2010.05.054. Epub 2010 Jun 4.

18.

Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O.

Brain. 2010 Feb;133(Pt 2):375-88. doi: 10.1093/brain/awp298. Epub 2010 Feb 9.

19.

DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN.

JAMA. 2009 Oct 28;302(16):1796-802. doi: 10.1001/jama.2009.1547.

20.

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA.

Nat Immunol. 2009 Nov;10(11):1185-92. doi: 10.1038/ni.1790. Epub 2009 Sep 27.

21.

Direct and consensual murine pupillary reflex metrics: establishing normative values.

Hussain RZ, Hopkins SC, Frohman EM, Eagar TN, Cravens PC, Greenberg BM, Vernino S, Stüve O.

Auton Neurosci. 2009 Dec 3;151(2):164-7. doi: 10.1016/j.autneu.2009.07.021. Epub 2009 Aug 15.

22.

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.

Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.

Arch Neurol. 2009 Aug;66(8):1016-20. doi: 10.1001/archneurol.2009.157. Erratum in: Arch Neurol. 2009 Nov;66(11):1384.

PMID:
19667224
23.

Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis.

Stüve O, Korth C, Gabatto P, Cameron EM, Hu W, Eagar TN, Monson NL, Frohman EM, Racke MK, Zabetian CP, Oksenberg JR.

Arch Neurol. 2009 Feb;66(2):280-1. doi: 10.1001/archneur.66.2.280. No abstract available.

PMID:
19204171
24.

PEG minocycline-liposomes ameliorate CNS autoimmune disease.

Hu W, Metselaar J, Ben LH, Cravens PD, Singh MP, Frohman EM, Eagar TN, Racke MK, Kieseier BC, Stüve O.

PLoS One. 2009;4(1):e4151. doi: 10.1371/journal.pone.0004151. Epub 2009 Jan 7.

25.

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O.

Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13.

PMID:
18852339
26.

B cells, antibodies, and tertiary lymphoid tissue in MS brains.

Stüve O, Eagar TN.

Lancet Neurol. 2008 Sep;7(9):766-7. doi: 10.1016/S1474-4422(08)70176-5. No abstract available.

PMID:
18702996
27.

DNA-based vaccines: the future of multiple sclerosis therapy?

Stüve O, Cravens PD, Eagar TN.

Expert Rev Neurother. 2008 Mar;8(3):351-60. doi: 10.1586/14737175.8.3.351. Review.

PMID:
18345967
28.

DNA plasmid vaccination for multiple sclerosis.

Stüve O, Eagar TN, Frohman EM, Cravens PD.

Arch Neurol. 2007 Oct;64(10):1385-6. No abstract available.

PMID:
17923622
29.

Prion proteins: physiological functions and role in neurological disorders.

Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, Hartung HP, Stüve O.

J Neurol Sci. 2008 Jan 15;264(1-2):1-8. Epub 2007 Aug 17. Review.

PMID:
17707411
30.

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA.

J Exp Med. 2006 Nov 27;203(12):2737-47. Epub 2006 Nov 20.

31.

Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

Smith CE, Eagar TN, Strominger JL, Miller SD.

Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9595-600. Epub 2005 Jun 27.

32.

CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance.

Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD.

J Immunol. 2004 Jun 15;172(12):7442-50.

33.

Notch 1 signaling regulates peripheral T cell activation.

Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA.

Immunity. 2004 Apr;20(4):407-15.

34.

Functional activation of myelin-specific T cells by virus-induced molecular mimicry.

Olson JK, Eagar TN, Miller SD.

J Immunol. 2002 Sep 1;169(5):2719-26.

35.

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.

Eagar TN, Karandikar NJ, Bluestone JA, Miller SD.

Eur J Immunol. 2002 Apr;32(4):972-81.

36.
37.

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, Kuchroo VK, Miller SD.

J Clin Invest. 2001 Apr;107(8):995-1006.

38.

CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis.

Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD.

J Neuroimmunol. 2000 Sep 22;109(2):173-80.

PMID:
10996219
39.

Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD.

J Immunol. 2000 Jan 15;164(2):670-8.

40.

The functional significance of epitope spreading and its regulation by co-stimulatory molecules.

Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD.

Immunol Rev. 1998 Aug;164:63-72. Review.

PMID:
9795764

Supplemental Content

Loading ...
Support Center